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Effect of dosing interval on efficacy of maropitant for prevention of
hydromorphone-induced vomiting and signs of nausea in dogs
Abstract
Objective—To evaluate the effect of dosing interval on the efficacy of maropitant for prevention of opioid-
induced vomiting and signs of nausea in dogs.
Design—Randomized prospective clinical study.
Animals—50 client-owned dogs that underwent an elective surgical procedure.
Procedures—Dogs were randomly assigned to receive maropitant (1 mg/kg [0.45 mg/lb], SC), then
hydromorphone (0.1 mg/kg [0.045 mg/lb], IM) at 0 (simultaneously; group 0; n = 10), 15 (group 15; 10),
30 (group 30; 10), 45 (group 45; 10), or 60 (group 60; 10) minutes later. Dogs were monitored for vomiting
and signs of nausea for 30 minutes after hydromorphone administration. A historical control group of similar
dogs (n = 9) that were administered hydromorphone (0.1 mg/kg, IM) but not maropitant served as the
referent for comparison purposes.
Results—Vomiting was recorded for 6 dogs in group 0 and 2 dogs in group 15. Signs of nausea were recorded
for 10 dogs in group 0, 9 dogs in group 15, 8 dogs in group 30, 6 dogs in group 45, and 1 dog in group 60.
Compared with dogs in the historical control group, vomiting was significantly decreased and prevented when
maropitant was administered 15 and 30 minutes, respectively, before hydromorphone; signs of nausea were
significantly decreased only when maropitant was administered 60 minutes before hydromorphone.
Conclusions and Clinical Relevance—Results indicated that vomiting was significantly decreased and then
prevented when maropitant was administered to dogs 15 and 30 minutes before hydromorphone. However,
signs of nausea were significantly decreased only when the dosing interval was 60 minutes.
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Effect of dosing interval on efficacy 
of maropitant for prevention of hydromorphone-
induced vomiting and signs of nausea in dogs 
Bonnie L. Hay Kraus, DVM 
Objective-To evaluate the effect of dosing interval on the efficacy of ma ropitant for pre-
vention of opioid-induced vomiting and signs of nausea in dogs. 
Design-Randomized prospective clinical study. 
Animals-50 client-owned dogs that underwent an elective surgical procedure. 
Procedures-Dogs were randomly assigned to receive maropitant (1 mg/kg [0.45 mg/lb], 
SC). then hydromorphone (0.1 mg/kg [0.045 mg/lb], IM) at 0 (simultaneously; group O; n 
= 10). 15 (group 15; 10), 30 (group 30; 10). 45 (group 45; 10), or 60 (group 60; 10) minutes 
later. Dogs were monitored for vomiting and signs of nausea for 30 minutes after hydro-
morphone administration. A historical control group of similar dogs (n = 9) that were ad-
ministered hydromorphone (0.1 mg/kg, IM) but not maropitant served as the referent for 
comparison purposes. 
Results- Vomiting was recorded for 6 dogs in group 0 and 2 dogs in group 15. Signs of 
nausea were recorded for 10 dogs in group 0, 9 dogs in group 15, 8 dogs in group 30, 6 dogs 
in group 45, and 1 dog in group 60. Compared with dogs in the historical control group, 
vomiting was significantly decreased and prevented when maropitant was administered 
15 and 30 minutes, respectively, before hydromorphone; signs of nausea were significantly 
decreased only when maropitant was administered 60 minutes before hydromorphone. 
Conclusions and Clinical Relevance-Results indicated that vomiting was significantly 
decreased and then prevented when maropitant was administered to dogs 15 and 30 min-
utes before hydromorphone. However, signs of nausea were signif icantly decreased only 
when the dosing interval was 60 minutes. (J Am Vet Med Assoc 2014;245:1015-1020) 
H ydromorphone is a synthetic µ-opioid receptor agonist that is commonly used alone or in combi-
nation with tranquilizers or sedatives as an anesthetic 
premedication, as part of an anesthesia induction regi-
men for high-risk patients, and as an intraoperative 
and postoperative analgesic. Hydromorphone does not 
cause histamine-induced vasodilation and hypotension 
following IV administration, and that property, along 
with its low cost, has contributed to the widespread use 
of hydromorphone for pain management in dogs. 1- 3 
In dogs, opioid administration frequently results 
in unwanted adverse effects, including bradycardia, re-
spiratory depression, behavior changes (eg, sedation, 
dysphoria, or excitement) , urine retention or decreased 
urine production, and gastrointestinal abnormalities 
(eg, signs of nausea, vomiting, and defecation). 4-6 Signs 
of nausea and vomiting occur frequently in dogs after 
administration of morphine, hydromorphone, and oxy-
morphone. The incidence of vomiting associated with 
hydromorphone administration ranges from 0% to 
100% and is dependent on the dose and route of admin-
istration, study conditions, population, duration that 
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food was withheld prior to administration, and concur-
rent administration of acepromazine.3.7- JO 
Vomiting during the perioperative period can result in 
aspiration of gastric contents, esophagitis and subsequent 
esophageal stricture, unnecessary tension on sutures, and 
increases in intracranial and intraocular pressures. Pro-
fuse or prolonged vomiting can cause dehydration, 
electrolyte and acid-base imbalances, and prolonged 
hospitalization.11 Thus, the avoidance and prevention 
of nausea and vomiting during the perioperative pe-
riod are important objectives in human medicine. Both 
human patients and anesthesiologists rate nausea and 
vomiting among the top anesthesia-associated adverse 
effects to be avoided.12 In fact, many human patients 
consider nausea and vomiting to be more distressing 
than postsurgical pain.12·13 In dogs, vomiting and re-
gurgitation, especially when associated with anesthesia 
and hydromorphone administration, are risk factors for 
the development of aspiration pneumonia. 14-18 Under-
lying gastrointestinal dysfunction, upper airway abnor-
malities, and surgical interventions put brachycephalic 
breeds of dogs at an increased risk of vomiting, regurgi-
tation, aspiration, and death during the perianesthetic 
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period, compared with those risks in the general canine 
population. 19•20 
Prevention of signs of nausea and vomiting during 
the perioperative period is garnering attention in vet-
erinary medicine. Maropitant is a highly selective NKl 
antagonist that was developed and approved for the 
treatment and prevention of vomiting in dogs. Clini-
cally, it is used to treat vomiting resulting from various 
causes and to prevent vomiting subsequent to a broad 
spectrum of emetic stimuli including motion sickness 
and administration of cisplatin, apomorphine, hydro-
morphone, morphine, or copper sulfate. 10·21- 27 
Results of a recent study10 indicate that maropitant 
(1.0 mg/kg [0.45 mg/lb], SC) effectively prevents signs 
of nausea and vomiting in dogs when administered 1 
hour prior to hydromorphone (O.l mg/kg [0.045 mg/ 
lb], IM). In another study,27 maropitant (1.0 mg/kg, 
SC) administered to dogs 20 minutes prior to mor-
phine (1.0 mg/kg IM) significantly decreased, but did 
not eliminate, vomiting and retching and had no effect 
on the incidence of signs of nausea, compared with 
those incidences for dogs that were administered saline 
(0 .9% NaCl) solution instead of maropitant prior to 
morphine. The objective of the study reported here was 
to evaluate the effect of dosing interval on the efficacy 
of maropitant for the prevention of hydromorphone-
induced vomiting and retching and signs of nausea. 
Materials and Methods 
Animals-Client-owned dogs~ 6 months old that 
were admitted to the Lloyd Veterinary Medical Center at 
Iowa State University between January and August 2012 
for elective surgery or advanced imaging that required 
anesthesia were considered for study enrollment. To be 
included in the study; each dog had to be classified as 
ASA28 status I (healthy with no evidence of systemic dis-
ease) or status II (mild systemic disease with no func-
tional limitations) on the basis of results of a complete 
physical examination, CBC, and serum biochemical 
analysis. The final study population consisted of 50 dogs 
(18 spayed females, 4 sexually intact females, 22 castrated 
males, and 6 sexually intact males) that ranged in age from 
6 months to 10.9 years and weight from 1.3 to 57.3 kg 
(2.9 to 126.1 lb) and included a mixture of purebred and 
mixed-breed dogs. Owner consent was obtained for each 
dog prior to study enrollment, and all study procedures 
were approved by the Iowa State University Institutional 
Animal Care and Use Committee. 
Study design-A card-draw technique29 was used 
to randomly assign each dog to 1 of 5 treatment groups. 
All dogs were premedicated with maropitant citrate• 
(1.0 mg/kg, SC) and then hydromorphone (0.1 mg/kg, 
IM) at 0 (ie, the same time; group O; n = 10), 15 (group 
15; 10), 30 (group 30; 10), 45 (group 45 ; 10), or 60 
(group 60; 10) minutes later. 
Food, but not water, was withheld from all dogs be-
ginning at 10:00 PM the night before anesthesia, which 
resulted in food being withheld from dogs for 8.5 to 15 
hours prior to maropitant administration. All SC injec-
tions were administered under the loose skin on the dor-
sal midline between the scapulae, and all IM injections 
were administered in the lumbar epaxial muscles. A 
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trained observer (BHK) monitored each dog for 30 min-
u tes after hydromorphone administration and recorded 
emetic events (vomiting and retching) and whether the 
dog had signs of nausea. This observer was aware of the 
treatment group assignment for each dog. Vomiting was 
defined as the expulsion of stomach contents from the 
mouth. Retching was defined as forceful contraction of 
abdominal muscles without expulsion of stomach con-
tents from the mouth. Each discrete vomiting or retching 
event was recorded. Signs of nausea were defined as sali-
vation and increased frequency of or exaggerated swal-
lowing motions and licking of lips; the presence of any of 
those signs was considered positive for signs of nausea. 
Dogs that vomited or retched were considered to have 
signs of nausea regardless of whether the other signs of 
nausea were observed because it is generally assumed 
that nausea is a prodromal sign of vomiting or retching. 
Historical control group-A group of dogs (n = 
9) that were administered saline (0.9% NaCl) solution 
1 hour prior to hydromorphone during another study10 
was used as a historical control group to serve as a refer-
ent for comparison with treatment groups of the present 
study. That study10 was approved by the Iowa State Uni-
versity Institutional Animal Care and Use Committee, 
and owner consent was obtained for each dog prior to 
study enrollment. Those dogs were similar to the dogs of 
the present study in that they were admitted to the Lloyd 
Veterinary Medical Center for an elective surgery and 
were classified as ASA status I or status II on the basis of 
results of a complete physical examination, CBC, and se-
rum biochemical analysis. The group consisted of a mix-
ture of purebred and mixed-breed dogs (6 females and 
3 males) with a mean± SD age of 5.3 ± 2.75 years and 
weight of 27 ± 16.5 kg (59.4 ± 36.3 lb) . All dogs were 
administered saline solution (O.l mUkg, SC) under the 
loose skin on the dorsal midline between the scapulae 
1 hour before hydromorphone (O.l mg/kg, IM) , which 
was injected in the lumbar epaxial muscles. The trained 
observer (BHK) that monitored the dogs of the present 
study also monitored each dog of that study10 for 30 min-
utes after hydromorphone administration and recorded 
emetic events (vomiting and retching) and whether the 
dog had signs of nausea. The definitions of vomiting, 
retching, and signs of nausea used in that study10 were 
the same as those used in the present study. 
Statistical analysis-A 1-way ANOVA was used to 
compare the mean age and weight among the treatment 
groups (groups 0, 15, 30, 45, and 60) and the historical 
control group. A X2 test was used to assess differences 
in the sex distribution between the respective treatment 
groups and the historical control group. The outcomes 
of interest were the incidence of emetic events (vomit-
ing or retching) and signs of nausea. A 2-tailed Fisher 
exact test was used compare the incidence of each out-
come between the respective treatment groups and the 
historical control group. For all analyses, values of P ~ 
0.05 were considered significant. 
Results 
The mean age (P = 0.589) and weight (P = 0.322) 
and sex distribution (P = 0.158) of dogs did not dif-
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Table 1-Number of dogs that vomited or retched and had signs of 
nausea within 30 minutes after hydromorphone (0.1 mg/kg [0.045 
mg/lb]. IM) administration following premedication with saline 
(0.9% NaCl) solution (0.1 mUkg, SC) 1 hour previously (historical 
control group) or maropitant (1.0 mg/kg [0.45 mg/lb]. SC) at 0 (ie, 
same time; group 0), 15 (group 15). 30 (group 30). 45 (group 45), or 
60 (group 60) minutes previously. 
No. of dogs Vomiting Signs of 
Treatment group in group or retching nausea 
Historical control 9 7 9 
0 10 6 10 
15 10 2* 9 
30 10 O* 8 
45 10 O* 6 
60 10 O* 1* 
All dogs were classified as ASA status I or status II on the basis of 
results of a physical examination, CBC, and serum biochemical analy-
sis. Vomiting was defined as the expulsion of stomach contents from 
the mouth. Retching was defined as forceful contraction of abdominal 
muscles without expulsion of stomach contents from the mouth. Signs of 
nausea were defined as salivation and increased frequency of or exag-
gerated swallowing motions and licking of lips; the presence of any of 
those signs was considered positive for signs of nausea. Dogs that vom-
ited or retched were considered to have signs of nausea regardless of 
whether the other signs of nausea were observed because it is generally 
assumed that nausea is a prodromal sign of vomiting or retching. 
*Within a column, value differs significantly (P~ 0.05) from that for 
the historical control group. 
fer significantly among the treatment groups and the 
historical control group. The number of dogs that 
vomited or retched and had signs of nausea within 30 
minutes after hydromorphone administration for each 
treatment group and the historical control group was 
summarized (Table 1) . The incidence of vomiting or 
retching was significantly (P = 0.023) less for group 15, 
compared with that for the historical control group. 
None of the dogs in groups 30, 45, and 60 vomited 
or retched within 30 minutes after hydromorphone 
administration, which suggested that administration 
of maropitant at least 30 minutes prior to hydromor-
phone prevented vomiting and retching. The respective 
incidences of signs of nausea for groups 0, 15, 30, and 
45 did not differ significantly from that for the histori-
cal control group. The incidence of signs of nausea for 
group 60 was significantly (P < 0.001) less than that 
for the historical control group, which suggested that 
administration of maropitant at least 60 minutes prior 
to hydromorphone reduced the occurrence of signs of 
nausea . 
Discussion 
Results of the present study indicated that admin-
istration of maropitant (1.0 mg/kg, SC) to dogs 1 hour 
prior to administration of hydromorphone (O.l mg/kg, 
IM) was effective in preventing vomiting and retch-
ing and reducing the incidence of signs of nausea and 
confirmed the findings of another study. 10 Further, in 
the present study, administration of maropitant as little 
as 15 minutes prior to hydromorphone administration 
was effective in reducing the incidence of vomiting 
and retching. This time frame was substantially shorter 
than that required for maropitant to reduce (30 min-
utes) and cease (39 minutes) cisplatin-induced emesis 
in dogs .2J Maropitant (1.0 mg/kg, SC) administration to 
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dogs achieves a Cmax of 92 ng/mL at 0.75 hours after 
injection.21 On the basis of the results of the present 
study, it appears that the antiemetic activity of maropi-
tant can be achieved well before the time required for 
the drug to reach its Cmax, especially when maropitant 
is administered before the emetic challenge (ie , before 
opioid administration) . However, the pharmacokinetic-
pharmacodynamic relationship of the NKl-antagonist 
activity of maropitant remains relatively unexplored. 
Neurokinin 1 antagonists (eg, maropitant) and 
their active metabolites have highly potent receptor-
binding affinity and are thought to penetrate the blood-
brain barrier and mediate their biological effect through 
occupation of NKl receptors in the brain.21 Because 
maropitant is highly protein bound, only a small frac-
tion of the total dose remains unbound to protein after 
injection and available to cross the blood-brain barrier 
to elicit pharmacological activity. 21 Results of 1 study2J 
indicate that the antiemetic activity of maropitant in 
dogs lasts for 19 hours following oral administration of 
2.0 mg of maropitant/kg, even when the mean plasma 
concentration of maropitant or its active metabolites is 
assumed to be < 40 ng/mL. In the present study, SC 
administration of maropitant to dogs 15 minutes before 
hydromorphone resulted in a significant reduction in 
the incidence of opioid-induced vomiting or retching, 
which provided further evidence that the in vivo activ-
ity of maropitant for prevention of opioid-induced em-
esis was achieved at plasma or CSF drug concentrations 
less than the Cmax. Additional research is warranted to 
determine the ability of maropitant and its active me-
tabolites to penetrate the blood-brain barrier and the 
concentration of maropitant in the plasma or CSF nec-
essary to induce its antiemetic effects. 
Although maropitant administration at least 15 
minutes before hydromorphone administration effec-
tively reduced or prevented vomiting or retching in the 
present study, a significant decrease in the incidence of 
signs of nausea was apparent only when maropitant was 
administered 60 minutes prior to hydromorphone. In 
human patients, nausea is subjectively described as an 
unpleasant sensation associated with the awareness of 
the urge to vomit.Jo The mechanisms that cause nausea 
remain unclear but are thought to be associated with 
stimuli from high brain centers that disrupt the normal 
contraction and relaxation patterns of the stomach,Jo 
which changes gastrointestinal motility and gastric acid 
secretion and causes reverse peristalsis.Jo Clinical signs 
associated with nausea in human patients include in-
creased salivation, pallor, tachycardia, hot and cold sen-
sations, and diaphoresis .J0 In dogs, nausea is described 
as a sensation that precedes vomiting and may or may 
not lead to vomiting, and the clinical signs of nausea in 
dogs include depression, salivation, licking of lips, and 
increased swallowing.J I Visual analogue scale scores for 
signs of nausea in dogs treated with apomorphine (ie, a 
centrally acting emetic) 1 hour after maropitant admin-
istration were lower than those for placebo-treated dogs 
during the first 12 minutes after apomorphine adminis-
tration. J2 However, when dogs were treated with syrup 
of ipecac (ie, a peripherally acting emetic), the VAS 
scores for signs of nausea for dogs that were premedi-
cated with maropitant, compared with those for dogs 
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that were premedicated with a placebo, did not differ 
significantly within the first 33 minutes after syrup of 
ipecac administration but were significantly lower be-
tween 36 and 60 minutes after syrup of ipecac admin-
istration.32 In both instances,32 maropitant significantly 
decreased but did not eliminate emesis, compared with 
a placebo, and it was more effective for reducing the in-
cidence of emesis than it was for reducing the incidence 
of signs of nausea. Healthy dogs that were administered 
maropitant immediately after cisplatin had significantly 
decreased VAS scores for signs of nausea for up to 80 
minutes, compared with control dogs that were admin-
istered saline solution instead of maropitant.23 Results 
of a recent study33 in which dogs were orally adminis-
tered maropitant (2.0 to 4.0 mg/kg [0.9 to 1.8 mg/lb]) or 
a lactose monohydrate placebo 2 hours prior to hydro-
morphone (0.1 mg/kg, IM) indicate that, although ma-
ropitant effectively prevented vomiting, 12 of 20 (60%) 
maropitant-treated dogs developed signs of nausea . In 
that study,33 of the 12 maropitant-treated dogs that de-
veloped signs of nausea, 10 had signs that were subjec-
tively classified as moderate or severe, whereas only 2 
of 16 placebo-treated dogs that developed signs of nau-
sea had signs that were classified as moderate or severe. 
Findings of the present study indicated that the inject-
able formulation of maropitant has a clear advantage 
over the oral formulation for the prevention of signs 
of nausea in dogs, although it must be administered at 
least 1 hour before opioid administration for this effect 
to be realized. 
A limitation of the present study was the failure to 
obtain VAS scores for signs of nausea for dogs in each of 
the treatment groups. This data would have allowed the 
severity of signs of nausea to be correlated with the dos-
ing interval between administration of maropitant and 
hydromorphone. The obvious advantage of maropitant 
administration to veterinary patients is the prevention 
of vomiting during the perioperative period and the as-
sociated decrease in patient morbidity and death; how-
ever, another advantage of maropitant administration is 
the reduction in patient discomfort caused by nausea. 
Human patients widely report that nausea causes dis-
comfort and distress. It should be assumed that nau-
sea may affect veterinary patients similarly, and steps 
should be taken to prevent or treat signs of nausea in 
those patients.34 
Another limitation of the present study is that the 
observer that recorded emetic events and the presence 
of signs of nausea was aware of (ie, not blinded to) the 
treatment group assignment for each dog, and that ob-
server's conscious or unconscious predisposition might 
have generated bias. In both human and veterinary 
medicine, many randomized clinical trials are conduct-
ed without the outcome assessor being blinded. Blind-
ing of outcome assessors can increase the time, cost, 
and logistic complexity of clinical trials and does not 
guarantee that the results will not be biased. However, 
results of multiple systematic reviews3S-37 indicate that 
observer bias tends to occur when nonblinded asses-
sors record measurement of scale, time-to-event, and 
binary outcomes. For randomized clinical trials with 
binary outcomes, use of nonblinded assessors biased 
treatment effect estimates and exaggerated ORs by 
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36%.37 However, in that systematic review,37 the pooled 
OR for blinded versus nonblinded assessors (ie, ob-
server bias) was 0.55 for randomized trials with subjec-
tive outcomes and 0.93 for randomized trials with less 
subjective outcomes, which suggested that there was 
very little difference between blinded and nonblinded 
observers. Bias is more likely to occur in trials with 
subjective measures than it is in trials with objective 
outcomes. The outcomes assessed in the present study 
were considered to be categorical and objective (ie, ei-
ther the dogs vomited, retched, or had signs of nausea 
or they did not during the 30 minutes after hydromor-
phone administration); subjective outcomes such as 
the measurement of the severity of the signs of nausea 
were not assessed. Therefore, blinding the observer was 
not considered necessary and likely would not have 
substantially affected the results or conclusions of this 
study; however, the presence of observer bias cannot be 
ruled out. 
The use of a historical control group from a study10 
performed by the same investigator at the same institu-
tion as the present study might also be considered a limi-
tation. Use of data from a historical control group has 
several advantages, including a reduction in the number 
of patients required for a clinical trial, which decreases 
the cost and shortens the duration of the trial. When the 
historical control group consists of subjects that received 
an ineffective treatment (ie, a placebo), use of data from 
those subjects may have an ethical advantage because 
fewer subjects receive the ineffective treatment. Addi-
tionally, reduced allocation of subjects to a placebo group 
might make recruitment easier and increase the feasibil-
ity of study completion.38 For those reasons, the use of 
historical control data has become increasingly impor-
tant in human clinical trials and has been used to some 
extent in veterinary medicine.39-43 In a seminal paper,43 
Pocock outlined the conditions for the acceptable use 
of data from a historical control group, which include 
the same criteria for subject enrollment, same methods 
for treatment evaluation, and comparable distribution of 
subject characteristics. Pocock's final condition is that 
the study for which use of a historical control group is 
being considered should be performed by the same or-
ganization with most of the same clinical investigators 
as the study that is providing the data for the historical 
control group. The present study fulfilled all the require-
ments for use of a historical control group. 
Maropitant administration to dogs and cats has gar-
nered the interest of clinicians because of its analgesic 
as well as its antiemetic properties. Neurokinin 1 recep-
tors and substance P are involved in pain perception via 
central and peripheral pathways that include sensory 
afferent fibers, dorsal root ganglia, the dorsal horn of 
the spinal cord, ascending spinal cord projections, and 
higher nerve centers.44 During a surgical procedure in 
which traction was applied to the ovarian ligament of 
female dogs and cats, administration of maropitant to 
the anesthetized animals caused a significant decrease 
in the minimum alveolar concentration of sevoflurane, 
compared with the minimum alveolar concentration of 
sevoflurane required for animals that did not receive 
maropitantH.45 The antiemetic, antinausea , and pos-
sible adjunct analgesic properties of maropitant make 
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it an attractive, cost-effective addition to sedatives and 
opioid analgesics in anesthetic premedication protocols 
for veterinary patients. 
In the present study, administration of maropitant 
to dogs at least 15 minutes before hydromorphone sig-
nificantly decreased the incidence of vomiting or retch-
ing during the first 30 minutes after hydromorphone 
administration, compared with that for dogs that did 
not receive maropitant prior to hydromorphone. How-
ever, maropitant had to be administered at least 60 min-
utes before hydromorphone to significantly decrease 
signs of nausea. Thus, for dogs in which the avoidance 
of vomiting and signs of nausea is imperative, maropi-
tant should be administered 1 hour prior to an opioid 
analgesic. The antiemetic, antinausea, and adjunct an-
algesic properties of maropitant make it an attractive 
alternative for inclusion in veterinary preanesthetic 
protocols. 
a. Cerenia, Zoetis, Florham Park, NJ. 
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From this month's AJVR ----------------
Multivoxel proton magnetic resonance spectroscopy 
of inflammatory and neoplastic lesions of the canine brain at 3.0 T 
Krystina L. Stad ler et al 
Objective-To describe findings of 3.0-T mu ltivoxe l proton magnetic reso nance spectroscopy ('H-
MRS) in dogs with inflammatory and neoplastic intracrania l disease and to determine the appli-
cab il ity of 'H-MRS for differentiating between inflammatory and neoplastic les ions and between 
meningiomas and gliomas. 
Animals-33 dogs wi th intracranial disease (19 neoplastic (10 meningioma, 7 glioma, and 2 other] 
and 14 inflammatory) . 
Procedures-3.0-T multivoxel 'H-MRS was performed on neoplastic or inflammatory intracranial 
lesions identifi ed with conventional MRI. N-acetylaspartate (NAA), choline, and creatine concentra -
tions were obtained retrospectively, and metabolite ratios were calculated. Values were compared 
for metabolites separate ly, between lesion categories (neopl astic or inflammatory), and between 
neoplastic lesion types (meningioma or glioma) by means of discriminant analysis and 1-way ANOVA. 
Results- Th e NAA-to-choline ratio was 82.7% (62/75) accurate for differentiating neoplastic from 
inflammatory intracranial lesions. Adding the NAA-to-creatine ratio or cho line-to-creatine rati o did 
not affect the accuracy of differentiation. Neoplastic lesions had lower NAA concentrations and 
higher choline concentrations than did inflammatory lesions. resu lting in a lower NAA-to-choline ra-
tio, lower NAA-to-creatine ratio, and higher choline-to-creatine ratio for neoplasia re lative to inflam-
mation . No significant metabolite differences between meningiomas and gliomas were detected. 
Conclusions and Clinical Relevance-'H-MRS was effective for differentiating inflammatory 
lesions from neoplastic lesions in dogs. Metabol ite alterations for 'H-MRS in neoplasia and in-
flammation were simi lar to changes described for humans. Use of 'H-MRS provided no additional 
information for differentiating between meningiomas and gliomas. Proton MRS may be a beneficia l 
adjunct to conventiona l MRI in patients with high clinical suspicion of inflammatory or neop lastic 
intracranial lesions. (Am J Vet Res 2014;75:982-989) 
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